Approval · Notice of Compliance 31670 · 2023
JALYN: Notice of Compliance 31670
Issued September 21, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31670
- Date
- September 21, 2023
- Company
- Glaxosmithkline IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of starting material manufacturing site. Change in the manufacturing process for the starting material.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| JALYN | Not yet assigned | — |
Medicinal ingredients
- TAMSULOSIN HYDROCHLORIDE 0.4 MG per CAP
- DUTASTERIDE 0.5 MG per CAP